(CTOR) Citius Oncology - Ratings and Ratios
Oncology, Therapeutics, Antibiotics
Description: CTOR Citius Oncology
Citius Oncology, Inc. (CTOR) is a US-based company operating in the Life Sciences Tools & Services sub-industry, with its common stock listed on NASDAQ. The companys market capitalization stands at $134.80M USD, indicating a relatively small-cap stock.
The absence of a Price-to-Earnings (P/E) ratio, both current and forward, suggests that the company is not profitable, which is further reinforced by a Return on Equity (RoE) of -68.38%. This indicates significant losses, potentially due to high operational expenses or investment in research and development.
Key economic drivers for CTOR likely include the success of its oncology-focused product pipeline, the competitive landscape of the life sciences tools and services industry, and the overall demand for cancer treatments. Key Performance Indicators (KPIs) to watch would include cash burn rate, research and development expenses as a percentage of revenue, and the progression of its clinical trials.
Given the companys negative RoE and lack of profitability, investors may be speculating on future potential rather than current earnings, which can lead to high volatility. The stocks beta of 3.015 indicates that it is more than three times as volatile as the overall market, suggesting a high-risk investment. Average trading volume is substantial at 371,400 shares, indicating liquidity but also potentially amplifying the impact of volatility.
Investors should closely monitor updates on the companys pipeline, financial health, and industry developments to assess potential for future profitability and stock performance. The high volatility and current lack of earnings suggest that investment in CTOR should be approached with caution and as part of a diversified portfolio.
CTOR Stock Overview
| Market Cap in USD | 150m |
| Sub-Industry | Life Sciences Tools & Services |
| IPO / Inception | 2022-12-08 |
CTOR Stock Ratings
| Growth Rating | -23.6% |
| Fundamental | 25.5% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | -3.89% |
| Analyst Rating | 3.0 of 5 |
CTOR Dividends
Currently no dividends paidCTOR Growth Ratios
| Growth Correlation 3m | -30.8% |
| Growth Correlation 12m | 31.1% |
| Growth Correlation 5y | 11.6% |
| CAGR 5y | -94.12% |
| CAGR/Max DD 3y | -0.95 |
| CAGR/Mean DD 3y | -0.97 |
| Sharpe Ratio 12m | -0.57 |
| Alpha | 0.49 |
| Beta | 0.709 |
| Volatility | 153.19% |
| Current Volume | 109.2k |
| Average Volume 20d | 146.9k |
| Stop Loss | 1.7 (-8.6%) |
| Signal | -0.20 |
Piotroski VR‑10 (Strict, 0-10) 0.0
| Net Income (-26.6m TTM) > 0 and > 6% of Revenue (6% = -360.3k TTM) |
| FCFTA 0.00 (>2.0%) and ΔFCFTA 1.22pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| error: NWC/Revenue cannot be calculated (needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA 0.00 (>3.0%) and CFO 126.3 > Net Income -26.6m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 0.35 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (71.6m) change vs 12m ago 7.55% (target <= -2.0% for YES) |
| error: Gross Margin (current vs previous) cannot be calculated (needs Total Revenue and Cost Of Revenue) |
| Asset Turnover -8.52% (prev 0.0%; Δ -8.52pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -158.5 (EBITDA TTM -25.5m / Interest Expense TTM 160.8k) >= 6 (WARN >= 3) |
Altman Z'' -8.06
| (A) -0.38 = (Total Current Assets 18.3m - Total Current Liabilities 53.0m) / Total Assets 91.7m |
| (B) -0.64 = Retained Earnings (Balance) -59.0m / Total Assets 91.7m |
| (C) -0.36 = EBIT TTM -25.5m / Avg Total Assets 70.5m |
| (D) -1.00 = Book Value of Equity -59.0m / Total Liabilities 59.3m |
| Total Rating: -8.06 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 25.50
| 1. Piotroski 0.0pt = -5.0 |
| 2. FCF Yield 0.00% = 0.00 |
| 3. FCF Margin -0.00% = -0.00 |
| 4. Debt/Equity 1.75 = 1.13 |
| 5. Debt/Ebitda -2.23 = -2.50 |
| 6. ROIC - WACC (= -66.04)% = -12.50 |
| 7. RoE -68.38% = -2.50 |
| 8. Revenue Trend data missing |
| 9. EPS Trend -62.67% = -3.13 |
What is the price of CTOR shares?
Over the past week, the price has changed by -2.11%, over one month by +6.29%, over three months by +33.81% and over the past year by +14.11%.
Is Citius Oncology a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of CTOR is around 1.68 USD . This means that CTOR is currently overvalued and has a potential downside of -9.68%.
Is CTOR a buy, sell or hold?
- Strong Buy: 0
- Buy: 0
- Hold: 1
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the CTOR price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | - | - |
| Analysts Target Price | - | - |
| ValueRay Target Price | 1.8 | -1.1% |
Last update: 2025-09-15 04:33
CTOR Fundamental Data Overview
CCE Cash And Equivalents = 112.0 USD (Cash And Short Term Investments, last quarter)
Revenue TTM is 0, using Net Income TTM -26.6m + Cost of Revenue 20.6m = -6.00m USD
P/E Forward = 38.1679
P/B = 4.6203
Beta = 3.01
Revenue TTM = -6.00m USD
EBIT TTM = -25.5m USD
EBITDA TTM = -25.5m USD
Long Term Debt = 3.80m USD (from longTermDebt, last quarter)
Short Term Debt = 53.0m USD (from totalCurrentLiabilities, last quarter)
Debt = 56.8m USD (Calculated: Short Term 53.0m + Long Term 3.80m)
Net Debt = 3.80m USD (from netDebt column, last quarter)
Enterprise Value = 206.5m USD (149.7m + Debt 56.8m - CCE 112.0)
Interest Coverage Ratio = -158.5 (Ebit TTM -25.5m / Interest Expense TTM 160.8k)
FCF Yield = 0.00% (FCF TTM 126.3 / Enterprise Value 206.5m)
FCF Margin = -0.00% (FCF TTM 126.3 / Revenue TTM -6.00m)
Net Margin = -442.6% (Net Income TTM -26.6m / Revenue TTM -6.00m)
Gross Margin = -442.6% ((Revenue TTM -6.00m - Cost of Revenue TTM 20.6m) / Revenue TTM)
Tobins Q-Ratio = -3.50 (set to none) (Enterprise Value 206.5m / Book Value Of Equity -59.0m)
Interest Expense / Debt = 0.28% (Interest Expense 160.8k / Debt 56.8m)
Taxrate = 21.0% (US default)
NOPAT = -25.5m (EBIT -25.5m, no tax applied on loss)
Current Ratio = 0.35 (Total Current Assets 18.3m / Total Current Liabilities 53.0m)
Debt / Equity = 1.75 (Debt 56.8m / last Quarter total Stockholder Equity 32.4m)
Debt / EBITDA = -2.23 (Net Debt 3.80m / EBITDA -25.5m)
Debt / FCF = 449.5k (Debt 56.8m / FCF TTM 126.3)
Total Stockholder Equity = 38.9m (last 4 quarters mean)
RoA = -28.98% (Net Income -26.6m, Total Assets 91.7m )
RoE = -68.38% (Net Income TTM -26.6m / Total Stockholder Equity 38.9m)
RoCE = -59.72% (Ebit -25.5m / (Equity 38.9m + L.T.Debt 3.80m))
RoIC = -59.72% (NOPAT -25.5m / Invested Capital 42.7m)
WACC = 6.32% (E(149.7m)/V(206.5m) * Re(8.63%)) + (D(56.8m)/V(206.5m) * Rd(0.28%) * (1-Tc(0.21)))
Shares Correlation 3-Years: -62.56 | Cagr: -2.08%
Discount Rate = 8.63% (= CAPM, Blume Beta Adj.)
[DCF Debug] Terminal Value 67.85% ; FCFE base≈126.3 ; Y1≈82.95 ; Y5≈37.94
Fair Price DCF = 0.00 (DCF Value 676.2 / Shares Outstanding 78.4m; 5y FCF grow -40.0% → 3.0% )
EPS Correlation: -62.67 | EPS CAGR: -15.51% | SUE: N/A | # QB: 0
Revenue Correlation: N/A | Revenue CAGR: 0.0% | SUE: N/A | # QB: None
Additional Sources for CTOR Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle